Education
About Us
Working with TipRanks
Follow Us
Orion Nutraceuticals, Inc. (TSE:ORI)
:ORI
RESEARCH TOOLSreports
Top Page
Orion Nutraceuticals
(ORI)
Rating:21Underperform
Price Target:―
Orion Nutraceuticals (ORI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$797.31K
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.00
Revenue GrowthN/A
EPS Growth-314.29%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength44
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding29,307,964
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-13.54
Price to Book (P/B)-10.61
Price to Sales (P/S)0.00
P/FCF Ratio-123.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Orion Nutraceuticals Business Overview & Revenue Model
Company DescriptionOrion Nutraceuticals Inc. focuses on the drug for treating asthma and chronic obstructive pulmonary diseases in Canada. The company was formerly known as Cline Capital Corp. Orion Nutraceuticals Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
How the Company Makes MoneyOrion Nutraceuticals generates revenue primarily through the sale of its nutraceutical products. The company's revenue model is based on direct sales to consumers through its online platform, as well as distribution partnerships with health stores and pharmacies. Key revenue streams include retail sales, subscription services for regular delivery of products, and wholesale agreements with healthcare providers. The company's earnings are bolstered by strategic partnerships with research institutions for product development and marketing collaborations with wellness influencers to expand its customer base.
Orion Nutraceuticals Financial Statement Overview
Summary
Orion Nutraceuticals is facing significant financial challenges, with no revenue generation and consistent losses impacting all aspects of its financial health. The balance sheet reflects high leverage and negative equity, while cash flow statements show persistent cash deficits, underscoring the need for strategic restructuring or new revenue streams to avoid further deterioration.Income Statement
The company has consistently reported zero revenue across all periods, indicating no sales activity. Negative EBIT and EBITDA margins highlight significant operational inefficiencies. The net profit margin is also deeply negative, reflecting ongoing losses.5
Very Negative
Balance Sheet
The balance sheet reveals negative stockholders' equity, implying financial instability and potential solvency issues. The company has a high debt-to-equity ratio, further increasing financial risk. The equity ratio is negative, emphasizing a precarious financial position.10
Very Negative
Cash Flow
Operating and free cash flows are consistently negative, indicating insufficient cash from operations to cover expenses. The operating cash flow to net income ratio is negative, aligning with poor income performance. Financing activities occasionally provide cash inflow, but not enough to stabilize cash flow concerns.15
Very Negative
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| -195.04K | -316.36K | -279.69K | -282.39K | -202.06K | -699.95K | EBITDA |
| -528.58K | -61.82K | -279.69K | 2.06M | -882.93K | -386.24K | Net Income Common Stockholders |
| -528.07K | -61.82K | -279.69K | -4.96M | -1.23M | -229.39K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 0.00 | 193.46K | 3.99K | 9.43K | 280.19K | 501.29K | Total Assets |
| 82.17K | 193.46K | 3.99K | 9.43K | 2.43M | 584.97K | Total Debt |
| 0.00 | 82.24K | 90.33K | 44.00K | 44.00K | 44.00K | Net Debt |
| 0.00 | -111.22K | 86.34K | 34.57K | -236.19K | -457.29K | Total Liabilities |
| 561.99K | 1.17M | 918.97K | 645.60K | 449.28K | 849.85K | Stockholders Equity |
| -479.82K | -975.87K | -914.05K | -635.25K | 1.98M | -263.96K |
| Cash Flow | Free Cash Flow | ||||
| -94.69K | -56.94K | -51.77K | -82.92K | -935.04K | -47.98K | Operating Cash Flow |
| -94.69K | -56.94K | -51.77K | -82.92K | -935.04K | -47.98K | Investing Cash Flow |
| 0.00 | 254.50K | 0.00 | -187.83K | -2.40M | 0.00 | Financing Cash Flow |
| -65.09K | -8.10K | 46.33K | 0.00 | 3.11M | 544.00K |
Orion Nutraceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | C$970.72K | 2.02 | -7.13% | ― | ― | -57.35% | |
54 Neutral | $5.38B | 3.40 | -45.06% | 3.28% | 16.75% | -0.02% | |
29 Underperform | C$1.08M | ― | -405.57% | ― | ― | -2291.11% | |
21 Underperform | C$797.31K | ― | 6.34% | ― | ― | -314.29% | |
21 Underperform | C$969.81K | ― | ― | ― | 81.21% | ||
| C$577.62K | ― | ― | ― | ― | |||
| $513.80K | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
TSE:ORI
Orion Nutraceuticals
0.40
0.00
0.00%
TSE:PHRX
Pharmadrug
0.01
-0.01
-50.00%
TSE:MGW
Maple Leaf Green World
0.02
-0.02
-50.00%
TSE:LRDS
Lords & Company Worldwide Holdings Inc
0.02
0.00
0.00%
TRLFF
Maven Brands Inc.
0.01
0.00
0.00%
TSE:STPH
Steep Hill Inc
0.06
0.03
100.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.